JP2018536393A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536393A5
JP2018536393A5 JP2018518451A JP2018518451A JP2018536393A5 JP 2018536393 A5 JP2018536393 A5 JP 2018536393A5 JP 2018518451 A JP2018518451 A JP 2018518451A JP 2018518451 A JP2018518451 A JP 2018518451A JP 2018536393 A5 JP2018536393 A5 JP 2018536393A5
Authority
JP
Japan
Prior art keywords
seq
region
antibody
fragment
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018518451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536393A (ja
JP6862435B2 (ja
Filing date
Publication date
Priority claimed from GBGB1517913.8A external-priority patent/GB201517913D0/en
Application filed filed Critical
Priority claimed from PCT/EP2016/073587 external-priority patent/WO2017060201A1/en
Publication of JP2018536393A publication Critical patent/JP2018536393A/ja
Publication of JP2018536393A5 publication Critical patent/JP2018536393A5/ja
Application granted granted Critical
Publication of JP6862435B2 publication Critical patent/JP6862435B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018518451A 2015-10-09 2016-10-04 抗wt1/hla特異的抗体 Expired - Fee Related JP6862435B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562239438P 2015-10-09 2015-10-09
GBGB1517913.8A GB201517913D0 (en) 2015-10-09 2015-10-09 Anti-WT1/HLA-specific antibodies
US62/239,438 2015-10-09
GB1517913.8 2015-10-09
EP15189753 2015-10-14
EP15189753.5 2015-10-14
PCT/EP2016/073587 WO2017060201A1 (en) 2015-10-09 2016-10-04 Anti-wt1/hla-specific antibodies

Publications (3)

Publication Number Publication Date
JP2018536393A JP2018536393A (ja) 2018-12-13
JP2018536393A5 true JP2018536393A5 (OSRAM) 2019-11-14
JP6862435B2 JP6862435B2 (ja) 2021-04-21

Family

ID=58487775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018518451A Expired - Fee Related JP6862435B2 (ja) 2015-10-09 2016-10-04 抗wt1/hla特異的抗体

Country Status (6)

Country Link
US (2) US10836829B2 (OSRAM)
EP (1) EP3359565A1 (OSRAM)
JP (1) JP6862435B2 (OSRAM)
HK (1) HK1258444A1 (OSRAM)
MA (1) MA45004A (OSRAM)
WO (1) WO2017060201A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP3366704A1 (en) * 2017-02-28 2018-08-29 Affimed GmbH Antibodies specific for mmp1/hla-a2 complex
JP2020523985A (ja) * 2017-05-31 2020-08-13 科済生物医薬(上海)有限公司Carsgen Therapeutics Co.,Ltd. 細胞免疫治療の組成物及び方法
ES2871146T3 (es) 2017-07-14 2021-10-28 Immatics Biotechnologies Gmbh Molécula de polipéptido con especificidad dual mejorada
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN111527107B (zh) 2017-12-21 2024-10-01 豪夫迈·罗氏有限公司 结合hla-a2/wt1的抗体
JP7470640B2 (ja) 2018-02-09 2024-04-18 イマティクス ユーエス,アイエヌシー. T細胞を製造する方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
US20200384028A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
MX2022010461A (es) 2020-02-24 2022-12-13 Immatics Us Inc Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022147029A2 (en) 2020-12-31 2022-07-07 Immatics US, Inc. Cd8 polypeptides, compositions, and methods of using thereof
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
WO2023025851A1 (en) 2021-08-24 2023-03-02 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
WO2023044488A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
JP2025516189A (ja) 2022-04-28 2025-05-27 イマティクス ユーエス,アイエヌシー. 膜結合型il-15、cd8ポリペプチド、細胞、組成物、およびそれらの使用方法
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
AU2024217436A1 (en) * 2023-02-06 2025-08-14 Eureka Therapeutics, Inc. Compositions including anti-wt-1 antibodies antigen binding fragments and uses thereof
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6082997B2 (ja) * 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター Hla−a2により提示されるwt1ペプチドへのt細胞受容体様抗体
US20140271644A1 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
EP3066131A1 (en) * 2013-11-07 2016-09-14 Memorial Sloan-Kettering Cancer Center Fc-enhanced anti-wt1/hla antibody
JP6553069B2 (ja) * 2013-11-07 2019-07-31 メモリアル スローン ケタリング キャンサー センター 抗wt1/hla二重特異性抗体
US20160152725A1 (en) * 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
US20190031759A1 (en) * 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.

Similar Documents

Publication Publication Date Title
JP2018536393A5 (OSRAM)
JP2017505125A5 (OSRAM)
JP2015535828A5 (OSRAM)
JP2020536488A5 (OSRAM)
JP2020500538A5 (OSRAM)
JP2012143232A5 (OSRAM)
JP2019536806A5 (OSRAM)
JP2013542194A5 (OSRAM)
RU2016129274A (ru) Канинизированные мышиные антитела к человеческому pd-1
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2015514110A5 (OSRAM)
JP2018521638A5 (OSRAM)
JP2013538057A5 (OSRAM)
JP2012116856A5 (OSRAM)
JP2015503909A5 (OSRAM)
JP2021500916A5 (OSRAM)
RU2015126533A (ru) Анти-cd47 антитела и способы их применения
JP2018535650A5 (OSRAM)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
HRP20160151T1 (hr) PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA
JP2012254092A5 (OSRAM)
JP2017525343A5 (OSRAM)
JP2023093753A5 (OSRAM)
RU2018120695A (ru) Связывающие молекулы, специфичные в отношении asct2, и их применения
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos